عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Last Surviving Member of 1st Team to Conquer Mount Everest Says it is Crowded, Dirty Now

Kanchha Sherpa sits on a chair during an interview with The Associated Press at his residence in Kathmandu, Nepal, Saturday, March 2, 2024. (AP Photo/Niranjan Shrestha)
Kanchha Sherpa sits on a chair during an interview with The Associated Press at his residence in Kathmandu, Nepal, Saturday, March 2, 2024. (AP Photo/Niranjan Shrestha)
TT
TT

Last Surviving Member of 1st Team to Conquer Mount Everest Says it is Crowded, Dirty Now

Kanchha Sherpa sits on a chair during an interview with The Associated Press at his residence in Kathmandu, Nepal, Saturday, March 2, 2024. (AP Photo/Niranjan Shrestha)
Kanchha Sherpa sits on a chair during an interview with The Associated Press at his residence in Kathmandu, Nepal, Saturday, March 2, 2024. (AP Photo/Niranjan Shrestha)

The only surviving member of the mountaineering expedition that first conquered Mount Everest said Saturday that the world's highest peak is too crowded and dirty, and the mountain is a god that needs to be respected.
Kanchha Sherpa, 91, was among the 35 members in the team that put New Zealander Edmund Hillary and his Sherpa guide Tenzing Norgay atop the 8,849-meter (29,032-foot) peak on May 29, 1953.
“It would be better for the mountain to reduce the number of climbers,” Kanchha said in an interview in Kathmandu on Saturday, “Right now there is always a big crowd of people at the summit.”
Since the first conquest, the peak has been climbed thousands of times, and it gets more crowded every year. During the spring climbing season in 2023, 667 climbers scaled the peak, but that brought in thousands of support staff to the base camp between the months of March and May.
There have been concerns about the number of people living on the mountain for months on end, generating trash and waste, but authorities have no plans to cut down on the number of permits they issue to climbers.
There are rules that require climbers to bring down their own trash, equipment and everything they carry to the mountain or risk losing their deposit, but monitoring has not been very effective, The Associated Press reported.
“It is very dirty now. People throw tins and wrappings after eating food. Who is going to pick them up now?” Kanchha said. “Some climbers just dump their trash in the crevasse, which would be hidden at that time but eventually it will flow down to base camp as the snow melts and carries them downward.”
For the Sherpas, Everest is Qomolangma or goddess mother of the world, and is revered by their community. They generally perform religious rituals before climbing the peak.
“They should not be dirtying the mountain. It is our biggest god and they should not be dirtying the gods,” he said “Qomolangma is the biggest god for the Sherpas but people smoke and eat meat and throw them on the mountain.”
Kanchha was just a young man when he joined the Hillary-Tenzing expedition. He was among the three Sherpas to go the last camp on Everest along with Hillary and Tenzing. They could not go any further because they did not have a permit.
They first heard of the successful ascent on the radio, and then were reunited with the summit duo at Camp 2.
“We all gathered at Camp 2 but there was no alcohol so we celebrated with tea and snacks,” he said. “We then collected whatever we could and carried it to base camp.”
The route they opened up from the base camp to the summit is still used by climbers. Only the section from the base camp to Camp 1 over the unstable Khumbu Icefall changes every year.
Kanchha has four children, eight grandchildren and a 20-month-old great-granddaughter.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”